ReviewFrontiers in pharmacology2026
The dysregulated unfolded protein response in diabetic kidney disease: mechanisms and crosstalk with cell death pathways.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease and end-stage kidney failure worldwide, yet the molecular mechanisms driving progressive renal injury remain incompletely understood. Chronic metabolic stress in diabetes disrupts endoplasmic reticulum (ER) homeostasis, leading to sustained activation of the unfolded protein response (UPR). While transient UPR signaling is adaptive and restores proteostasis, persistent ER stress in the diabetic milieu shifts UPR signaling toward maladaptive pathways that promote cellular dysfunction and death. This review summarizes the canonical UPR branches mediated by protein kinase RNA-like ER kinase (PERK), inositol-requiring enzyme 1α (IRE1α), and activating transcription factor 6 (ATF6), and discusses their dysregulation in the diabetic kidney. We highlight how chronic glucolipotoxicity, oxidative stress, and protein overload drive prolonged UPR activation in podocytes and tubular epithelial cells, leading to loss of proteostatic balance and progressive nephron injury. Importantly, emerging evidence indicates that UPR signaling interacts with multiple regulated cell death pathways, including apoptosis, autophagy dysfunction, ferroptosis, pyroptosis, and necroptosis, forming a pathological crosstalk network that determines renal cell fate. This maladaptive integration amplifies inflammation, oxidative stress, mitochondrial dysfunction, and fibrotic remodeling, ultimately contributing to podocyte depletion, tubular atrophy, and disease progression. Finally, we discuss therapeutic strategies to restore ER proteostasis and modulate UPR-mediated cell death signaling, highlighting their potential as disease-modifying approaches in DKD. A deeper understanding of UPR dysregulation and its interaction with cell death pathways may provide novel mechanistic insights and facilitate the development of targeted therapies for diabetic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.